SALT LAKE CITY, May 17, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today reported financial results for its third fiscal quarter ended March 31, 2010. The Company ended the quarter with $148.4 million in cash, cash equivalents and marketable securities and subsequently received a payment of $12.7 million from Javelin Pharmaceuticals, Inc. pursuant to the termination of the proposed merger agreement between the companies.
